K Matter-Walstra
Cost-effectiveness of nivolumab in the treatment of head and neck cancer
Hirschmann A, Lupatsch J, Schwenkglenks M, Panje C, Matter-Walstra K, Espeli V, Dedes K, Siano M, Swiss Group of Clinical Cancer Research (SAKK). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncol 2018; 87:104-110.
30.10.2018Cost-effectiveness of nivolumab in the treatment of head and neck cancer
30.10.2018Oral Oncol 2018; 87:104-110
Hirschmann A, Lupatsch J E, Schwenkglenks M, Panje Cédric, Matter-Walstra K, Espeli V, Dedes K J, Siano Marco, Swiss Group of Clinical Cancer Research (SAKK)
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes K. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer Res Treat 2016; 158:51-7.
08.06.2016Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
08.06.2016Breast Cancer Res Treat 2016; 158:51-7
Matter-Walstra K, Ruhstaller Thomas, Klingbiel D, Schwenkglenks M, Dedes K J
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
Jörger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, Cerny T. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 2014; 70:719-25.
11.03.2014Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
11.03.2014Eur J Clin Pharmacol 2014; 70:719-25
Jörger Markus, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem Stefan, Thürlimann Beat, Cerny Thomas
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
04.01.2012Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
04.01.2012Ann Oncol 2012; 22:567-574
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis
Jörger M, Matter-Walstra K, Früh M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis. Ann Oncol 2012; 22:567-574.
01.01.2012Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis
01.01.2012Ann Oncol 2012; 22:567-574
Jörger Markus, Matter-Walstra K, Früh Martin
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
13.09.2010Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
13.09.2010Ann Oncol 2010; 22:567-74
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M